The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC).
Eric Pujade-Lauraine
No relevant relationships to disclose
Beatrice E. Weber
No relevant relationships to disclose
Isabelle Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche
Research Funding - PharmaMar; Roche
Ignace Vergote
Consultant or Advisory Role - Boehringer Ingelheim
Frédéric Selle
No relevant relationships to disclose
Jose Maria Del Campo
No relevant relationships to disclose
Jozef Sufliarsky
Research Funding - Boehringer Ingelheim
Inga Tschöpe
Employment or Leadership Position - Boehringer Ingelheim
Pilar Garin Chesa
Employment or Leadership Position - Boehringer Ingelheim
Serge Nazabadioko
Employment or Leadership Position - Boehringer Ingelheim
Korinna Pilz
Employment or Leadership Position - Boehringer Ingelheim
Florence Joly
Consultant or Advisory Role - PharmaMar; Roche
Honoraria - PharmaMar; Roche